Aurobindo Pharma has informed that the US Food and Drug Administration (FDA) had conducted an inspection at the Unit IV, a Formulation manufacturing facility, of APL Healthcare, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023. The Unit has now received Establishment Inspection Report classifying the facility as ‘Voluntary Action Indicated’ (VAI).
The above information is a part of company’s filings submitted to BSE.
